Mindset operates a platform for developing an IP portfolio of next-generation psychedelic medicines and related manufacturing processes.
Investment Highlights
Mindset is developing superior psychedelic medications to better meet the needs of patients
First mover IP advantage, advancing 4 families of novel, optimized, drugs to the clinic
Groundbreaking partnership with Otsuka Pharmaceutical – a top global neuroscience pharma company – to accelerate commercialization of multiple new drug families
The leading drug discovery platform of the medical psychedelic space, led by accomplished drug discovery scientists
Analyst Coverage
Firm
Analyst
Maxim Group LLC
Michael Okunewitch
H.C. Wainwright & Co.
Patrick R. Trucchio, CFA
Echelon Capital Markets
Stefan Quenneville, CFA
Mindset Pharma Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Mindset Pharma Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Mindset Pharma Inc. or its management. Mindset Pharma Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
